Please type	a plus	sign (+)	inside this	box→	+
, p.	o p	0.0 ( . /	413100 0113	UUX	

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031\* and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	Substitute fo	or form 1449A/F	OTO		Complete if Known				
					Application Number	Unassigned			
	INFOF	RMATIO	N DIS	CLOSURE	Filing Date	April 29, 2005			
	STATI	EMENT	BY AI	PPLICANT	First Named Inventor	Hans-Georg KREYSCH			
					Group Art Unit	Unassgiend			
	(0	use as many s	sheets as	necessary)	Examiner Name	Unassigned			
_	Sheet	1	of	2	Attorney Docket Number	MERCK-2989			

U.S. PATENT DOCUMENTS							
Examiner initials	Cite Na.¹	U.S. Patent Docu	ment Kind Code <sup>z</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
X	_ 1	5587458			December 24, 1996		
W.							
		<del></del>		· · · · · · · · · · · · · · · · · · ·			
			<del>-    </del>				
	<del>  -</del>		<del>-  </del>				
		<del> </del>					

FOREIGN PATENT DOCUMENTS								
		Foreign Patent Document			Date of Publication of	Pagas, Columns, Lines, Where Relevant		
Examiner Initials*/	Cite No.'	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>s</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	To.
1	2	wo	02055106		Merck Patent GmbH	July 18, 2002		
77 \	<del></del>	wo	9400136		Molecular Oncology Inc.	January 6, 1994		Equv to cite 1
7								
				1				
			•	ĺ				

		 /	
Examiner Signature	PD	Date Considered	6/27/06

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3), <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	Substitute	for form 1449A/P	то		Complete If Known		
	INICOI	314 A TIO		001105	Application Number	Unassigned	
				OSURE	Filing Oate	April 29, 2005	
	STAT	EMENT I	BY APP	LICANT	First Named Inventor	Hans-Georg KREYSCH	
					Group Art Unit	Unassigend	
	(	use as many s	heets as nec	essary)	Examiner Name	Unassigned	
て	Sheet	2	of	2	Attorney Docket Number	MERCK-2989	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journel, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
X	L 4	YE D ET AL: "AUGMENTATION OF A HUMANIZED ANTI-HER2 MAB 4D5 INDUCED GROWTH INHIBITION BY A HUMAN-MOUSE CHIMERIC ANTI-EGF RECEPTOR MAB C225" ONCOGENE, BASINGSTOKE, HANTS, GB, VOL. 18, NO. 3, JANUARY 21, 1999 731-738, XP001096335	٠
	. 5	SCHMIDT M ET AL: "A BIVALENT SINGLE-CHAIN ANTIBODY-TOXIN SPECIFIC FOR ERB-2 AND THE EFG RECEPTOR" INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, VOL. 65, NO. 4, FEBRUARY 8, 1996 PAGES 538-546, XP000646380	
	6	KASPRZYK P G ET AL: "THERAPY OF AN ANIMAL MODEL OF HUMAN GASTRIC CANCER USING A COMBINATION OF ANTI-ERBB-2 MONOCLONAL ANTIBODIES" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, VOL. 52, 15 MAY 1992, PAGES 2771-2776, XP001093195	
V	7	BASELGA J ET AL: "PHASE II STUDY OF WEEKLY INTRAVENOUS RECOMBINANT HUMANIZED ANTI-P185HER2 MONOCLONAL ANTIBDY IN PATIENTS WITH HER2/NEU-OVEREXPRESSING METASTATIC BREAST CANCER" JOURNAL OF CLINICAL ONCOLOGY, PHILADELPHIA, PA, US, VOL. 14, NO. 3, MARCH 1996 PAGES 737-744, XP000918166.	

Examiner Date (a/2.7/AC				
Signature Considered 4/21/00	Examiner Signature	XXX	Date Considered	6/27/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case, Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.